Effect of prior therapy on tumor mutational burden in NSCLC


Sushma Jonna 1, Ari Vanderwalde 2, Jorge Nieva 3, Kelsey Anne Poorman 4, Michelle Saul 4, Xinyu von Buttlar 5, John Y Hu 6, Stephen V Liu 5

Background: Higher tumor mutation burden (TMB) in advanced non-small cell lung cancer (NSCLC) is associated with superior outcomes with checkpoint inhibitor therapy. Tissue samples subject to TMB analysis may be acquired after DNA-damaging therapies such as chemotherapy or radiation. The impact of these therapies on TMB results is unclear. This retrospective analysis explored differences in TMB among treatment-naïve samples and treatment-experienced samples.

External Link